Smart Patients Get Smart Care™
The World’s Leading Authority for Chronic Lymphocytic Leukemia Patients
Most people who have been diagnosed with CLL or SLL have no symptoms initially and are usually advised that no treatment is necessary upon diagnosis
Join the CLL Society and Nurse Practitioner Laura Zitella, who will discuss the timing of CLL treatment and the various factors to consider when navigating your disease journey.
At the annual meeting of the American Society of Hematology (ASH) 2021, our own Dr. Brian Koffman, interviewed Dr. Stephan Stilgenbauer, Professor of Medicine at the Comprehensive Cancer Center at Ulm University in Germany. They discussed the latest results from the GAIA (CLL13) trial, which compared rates of measurable residual disease (MRD) with the different treatments.
Our own Dr. Koffman is quoted in his local paper, the LA Times, in this article: This Treatment Can Protect Vulnerable People From COVID. But Many Don’t Know About It.
The team at Dana-Farber Cancer Institute is testing whether the combination of duvelisib (Copiktra™) and venetoclax (Venclexta®) will lead to deep remissions that would allow for oral only therapy of one year duration. Learn more about this ongoing Phase I/II clinical trial.
It’s been a month since my last post on progress in my trial of epcoritamab, a bispecific T cell engager (BiTE) for my chronic lymphocytic leukemia.
Early data on combination sonrotoclax plus zanubrutinib for previously untreated CLL / SLL is very promising.
Most resistance mutations acquired by CLL patients during zanubrutinib treatment occurred at a single site on BTK.
A one page summary of what you need to know about the 3 most important tests that need to be done to guide your CLL treatment.
One click to our most popular content.
